biology-products/custom-peptide-synthesis-from-raybiotech--inc--4742-1/;/a><br

Breaking Biology Technology:Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4 AEterna Zentaris Announces Appointment of New Board Member 2 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4 CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 2 CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 3

[0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea [0] AEterna Zentaris Announces Appointment of New Board Member [0] Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics [0] CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner

Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4 New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2 New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3 New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4 VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 1 VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 2 VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 1 VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 2 Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 1 Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 2 Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 3

[0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug [0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology [0] New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals